MA53338A - Dosages pour détecter la neurodégénérescence - Google Patents

Dosages pour détecter la neurodégénérescence

Info

Publication number
MA53338A
MA53338A MA053338A MA53338A MA53338A MA 53338 A MA53338 A MA 53338A MA 053338 A MA053338 A MA 053338A MA 53338 A MA53338 A MA 53338A MA 53338 A MA53338 A MA 53338A
Authority
MA
Morocco
Prior art keywords
assays
neurodegeneration
detecting
detecting neurodegeneration
Prior art date
Application number
MA053338A
Other languages
English (en)
Inventor
Hartmuth Christian Kolb
John Randall Slemmon
Gallen Triana-Baltzer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA53338A publication Critical patent/MA53338A/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40Concentrating samples
    • G01N1/4005Concentrating samples by transferring a selected component through a membrane
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N2030/022Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027Liquid chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2828Prion diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA053338A 2018-03-05 2019-03-04 Dosages pour détecter la neurodégénérescence MA53338A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862638524P 2018-03-05 2018-03-05

Publications (1)

Publication Number Publication Date
MA53338A true MA53338A (fr) 2022-01-05

Family

ID=67768541

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053338A MA53338A (fr) 2018-03-05 2019-03-04 Dosages pour détecter la neurodégénérescence

Country Status (16)

Country Link
US (3) US10591492B2 (fr)
EP (1) EP3762414A4 (fr)
JP (2) JP7399096B2 (fr)
KR (2) KR20240150533A (fr)
CN (1) CN112105640A (fr)
AU (1) AU2019232630A1 (fr)
BR (1) BR112020018193A2 (fr)
CA (1) CA3093198A1 (fr)
EA (1) EA202092087A1 (fr)
IL (1) IL277077A (fr)
JO (1) JOP20200216A1 (fr)
MA (1) MA53338A (fr)
MX (1) MX2020009278A (fr)
PH (1) PH12020551371A1 (fr)
SG (1) SG11202008574VA (fr)
WO (1) WO2019171258A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021065306A1 (fr) * 2019-09-30 2021-04-08
WO2022013286A1 (fr) * 2020-07-14 2022-01-20 Janssen Pharmaceutica Nv Dosage sanguin permettant la détection d'une tauopathie ou d'une maladie amyloïdogène
MX2023004831A (es) 2020-10-26 2023-07-12 Janssen Pharmaceutica Nv Metodos para reducir tau en sujetos humanos.
AU2022222134A1 (en) * 2021-02-19 2023-07-13 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody
CA3233533A1 (fr) * 2021-10-01 2023-04-06 Todd Flower Methodes et dispositifs de detection de fuite de liquide cephalo-rachidien
WO2023092004A1 (fr) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à tau
CN114778856B (zh) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 磷酸化tau蛋白检测试剂盒
WO2024214588A1 (fr) * 2023-04-13 2024-10-17 国立研究開発法人量子科学技術研究開発機構 Procédé et dispositif d'estimation de la quantité d'accumulation de protéine tau dans le cerveau d'un sujet
JP7450995B1 (ja) 2023-04-13 2024-03-18 国立研究開発法人量子科学技術研究開発機構 被験者の脳のタウタンパク質の蓄積量を推定する方法及び装置

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
WO1995017429A1 (fr) 1993-12-21 1995-06-29 Innogenetics N.V. Anticorps monoclonaux specifiques de phf-tau, hybridomes les secretant, reconnaissance des antigenes par ces anticorps et leurs applications
DE69529906D1 (de) 1994-07-29 2003-04-17 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
CN1230174C (zh) 1999-07-06 2005-12-07 伊莱利利公司 治疗偏头痛的选择性iGluR5受体拮抗剂
DE60141752D1 (de) 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
ES2352668T3 (es) 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
EP3329932A1 (fr) * 2009-06-10 2018-06-06 New York University Ciblage immunologique de protéines tau pathologiques
EP2470211B1 (fr) 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Anticorps liant les oligomères de la protéine tau
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CN107226863B (zh) * 2011-12-20 2021-06-01 詹森生物科技公司 抗PHF-tau抗体及其用途
WO2014011972A1 (fr) 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Immunodosage de tau
AU2013361107B2 (en) * 2012-12-21 2018-08-23 Biogen International Neuroscience Gmbh Human anti-tau antibodies
CN105939722A (zh) * 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
EP3160998B1 (fr) * 2014-06-26 2019-08-21 Janssen Vaccines & Prevention B.V. Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
MX2017010919A (es) * 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
KR20180014764A (ko) * 2015-06-05 2018-02-09 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
CN109415434B (zh) * 2016-05-02 2022-12-30 普罗塞纳生物科学有限公司 识别tau的抗体
US12049506B2 (en) * 2021-03-18 2024-07-30 Medimmune Limited Therapeutic binding molecules

Also Published As

Publication number Publication date
US20200182888A1 (en) 2020-06-11
CN112105640A (zh) 2020-12-18
JP2024037794A (ja) 2024-03-19
EA202092087A1 (ru) 2020-11-17
JP7399096B2 (ja) 2023-12-15
SG11202008574VA (en) 2020-10-29
JP2021517239A (ja) 2021-07-15
EP3762414A1 (fr) 2021-01-13
KR20240150533A (ko) 2024-10-15
PH12020551371A1 (en) 2021-08-23
KR102716144B1 (ko) 2024-10-10
US20200408781A1 (en) 2020-12-31
MX2020009278A (es) 2021-01-08
WO2019171258A1 (fr) 2019-09-12
AU2019232630A1 (en) 2020-09-24
US20190271710A1 (en) 2019-09-05
CA3093198A1 (fr) 2019-09-12
EP3762414A4 (fr) 2022-01-05
BR112020018193A2 (pt) 2021-02-02
IL277077A (en) 2020-10-29
US10976325B2 (en) 2021-04-13
US10591492B2 (en) 2020-03-17
JOP20200216A1 (ar) 2020-09-03
KR20200130354A (ko) 2020-11-18

Similar Documents

Publication Publication Date Title
MA53338A (fr) Dosages pour détecter la neurodégénérescence
HRP20190026T1 (hr) Testovi za određivanje prisutnosti ili količine protutijela protiv lijeka
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA46057A (fr) Anticorps anti-ctla4
DK3455257T3 (da) Anti-pd-l1-antistoffer
FR3044432B1 (fr) Systeme d'actionnement pour aeronef.
MA52366A (fr) Anticorps anti-tl1a optimisés
MA52191A (fr) Carrosserie ouvrante pour une sous-structure
FR3042807B1 (fr) Autolestage pour banche de coffrage
MA52545A (fr) Anticorps pour radionucléides chélatés
DK3328886T3 (da) Tungkæde antistoffer over for ang-2
MA42706A (fr) Anticorps et dosages pour la détection de cd37
FR3047059B1 (fr) Ensemble de raccord pour tube
ES2985624T3 (es) Ensayo de detección
MA53160A (fr) Récepteur pour vista
DK3775180T3 (da) Biosensor til diagnosticering af thyroideadysfunktion
FR3039220B1 (fr) Dipositif de postcombustion pour turboreacteur
MA54500A (fr) Vitre pour un véhicule
DK3849976T3 (da) GABAA-receptorligand
FR3046351B1 (fr) Chariot- portoir pour brancard.
FR3046350B1 (fr) Chariot- portoir pour un brancard.
FR3049751B1 (fr) Perfectionnement pour accordeon
JP1672956S (ja) 液体注出具